ArticleExpert review of anti-infective therapy2012
Parasites in the brain? The search for sleeping sickness biomarkers.
Article in Expert review of anti-infective therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- NTD Diagnostics for Disease Elimination: A Review.Diagnostics (Basel, Switzerland) · 2020Review
- The miRNA and mRNA Signatures of Peripheral Blood Cells in Humans Infected with Trypanosoma brucei gambiense.PloS one · 2013Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evaluation of: Tiberti N, Hainard A, Lejon V et al. Cerebrospinal fluid neopterin as marker of the meningo-encephalitic stage of Trypanosoma brucei gambiense sleeping sickness. PLoS ONE 7(7), e40909 (2012). Human African trypanosomiasis (HAT) is a fatal parasitic disease that progresses from an early stage (stage 1), where parasites multiply in the hemolymphatic system, to a late stage (stage 2) disease, where parasites have become manifest within the CNS. Patients with stage 1 disease are treated with relatively safe drugs, but stage 2 disease requires treatment with drugs that are very toxic or difficult to administer. Thus, it is important to determine the stage of HAT infection before treating. HAT staging currently involves microscopic examination of cerebrospinal fluid (CSF), looking for the presence of parasites, or for more than five white blood cells per microliter CSF. This article tested the specificity and selectivity of eight potential CSF markers for stage 2 HAT, by analysis of levels in 400 CSF samples from patients diagnosed with stage 1 or stage 2 HAT by WHO protocols. Two of these markers gave results that were comparable with those obtained by conventional diagnosis. The potential for and challenges of developing improved staging for HAT are discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.